Pyelonephritis cost-effectiveness of therapy

Jump to navigation Jump to search

Urinary Tract Infections Main Page

Pyelonephritis Microchapters


Patient Information


Historical Perspective




Differentiating Pyelonephritis from other Diseases

Epidemiology and Demographics

Risk Factors


Natural History, Complications and Prognosis


Diagnostic Study of choice

History and Symptoms

Physical Examination

Laboratory Findings


X Ray

Echocardiography and Ultrasound

CT scan


Other Imaging Findings

Other Diagnostic Studies


Medical Therapy



Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Pyelonephritis cost-effectiveness of therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides


American Roentgen Ray Society Images of Pyelonephritis cost-effectiveness of therapy

All Images
Echo & Ultrasound
CT Images

Ongoing Trials at Clinical

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pyelonephritis cost-effectiveness of therapy

CDC on Pyelonephritis cost-effectiveness of therapy

Pyelonephritis cost-effectiveness of therapy in the news

Blogs on Pyelonephritis cost-effectiveness of therapy

Directions to Hospitals Treating Pyelonephritis

Risk calculators and risk factors for Pyelonephritis cost-effectiveness of therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Usama Talib, BSc, MD [2]


According to an estimate the mean cost of diagnosing and managing a patient with urinary tract infection including pyelonephritis is more than 229 pounds per year. Hyaluronan therapy given long term cuts down the cost of multiple pretreatments as it prevents recurrence of a urinary tract infection.[1][2]

Cost Effectiveness of therapies


  1. 1.0 1.1 Riedl C, Engelhardt P, Schwarz B (2013). "Treatment costs of bladder pain syndrome/interstitial cystitis in Austria: a pharmacoeconomic approach following current guidelines". Clin Drug Investig. 33 (10): 737–42. doi:10.1007/s40261-013-0119-4. PMID 23921624.
  2. 2.0 2.1 Ciani O, Grassi D, Tarricone R (2013). "An economic perspective on urinary tract infection: the "costs of resignation"". Clin Drug Investig. 33 (4): 255–61. doi:10.1007/s40261-013-0069-x. PMID 23475540.
  3. 3.0 3.1 Jakobi P, Goldstick O, Finkelstein R, Itzkovitz-Eldor J (1998). "[Empirical treatment of urinary tract infections in the delivery room--findings and desires]". Harefuah. 135 (9): 344–7, 408. PMID 10911441.
  4. Huang ES, Stafford RS (2002). "National patterns in the treatment of urinary tract infections in women by ambulatory care physicians". Arch Intern Med. 162 (1): 41–7. PMID 11784218.

Template:WH Template:WS